179 related articles for article (PubMed ID: 38595192)
1. Definitions and unmet needs in the management of oligomestatic renal cell carcinoma in the modern era.
Francolini G; Campi R; Ciccarese C;
Curr Opin Urol; 2024 Jul; 34(4):300-306. PubMed ID: 38595192
[TBL] [Abstract][Full Text] [Related]
2. Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions.
Donini M; Buti S; Massari F; Mollica V; Rizzo A; Montironi R; Bersanelli M; Santoni M
Expert Rev Anticancer Ther; 2020 Jun; 20(6):491-501. PubMed ID: 32479120
[TBL] [Abstract][Full Text] [Related]
3. Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology.
Alhalabi O; Karam JA; Tannir NM
Curr Opin Urol; 2019 Sep; 29(5):521-525. PubMed ID: 31305271
[TBL] [Abstract][Full Text] [Related]
4. Redefining the Role of Surgical Management of Metastatic Renal Cell Carcinoma.
Hsiang WR; Kenney PA; Leapman MS
Curr Oncol Rep; 2020 Mar; 22(4):35. PubMed ID: 32170461
[TBL] [Abstract][Full Text] [Related]
5. The use of cytoreductive nephrectomy in patients with renal cell carcinoma.
Ghandour RA; Singla N; Margulis V
Expert Rev Anticancer Ther; 2019 May; 19(5):405-411. PubMed ID: 31020871
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy.
Kwan KG; Kapoor A
Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804
[TBL] [Abstract][Full Text] [Related]
7. A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.
Singh AK; Winslow TB; Kermany MH; Goritz V; Heit L; Miller A; Hoffend NC; Stein LC; Kumaraswamy LK; Warren GW; Bshara W; Odunsi K; Matsuzaki J; Abrams SI; Schwaab T; Muhitch JB
Clin Cancer Res; 2017 Sep; 23(17):5055-5065. PubMed ID: 28630212
[No Abstract] [Full Text] [Related]
8. Is cytoreductive nephrectomy relevant in the immunotherapy era?
Singla N; Ghandour RA; Margulis V
Curr Opin Urol; 2019 Sep; 29(5):526-530. PubMed ID: 31305273
[TBL] [Abstract][Full Text] [Related]
9. Metastasectomy in patients with renal cell carcinoma: when and how?
Omid S; Abufaraj M; Remzi M
Curr Opin Urol; 2020 Jul; 30(4):602-609. PubMed ID: 32464043
[TBL] [Abstract][Full Text] [Related]
10. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
11. Spine stereotactic radiosurgery with concurrent tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Miller JA; Balagamwala EH; Angelov L; Suh JH; Rini B; Garcia JA; Ahluwalia M; Chao ST
J Neurosurg Spine; 2016 Dec; 25(6):766-774. PubMed ID: 27391397
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Patients with Metastatic Renal Cell Carcinoma Undergoing Deferred, Upfront, or No Cytoreductive Nephrectomy in the Era of Combination Immunotherapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Takemura K; Ernst MS; Navani V; Wells JC; Bakouny Z; Donskov F; Basappa NS; Wood LA; Meza L; Pal SK; Szabados B; Powles T; Beuselinck B; McKay RR; Lee JL; Ernst DS; Kapoor A; Yuasa T; Choueiri TK; Heng DYC
Eur Urol Oncol; 2024 Jun; 7(3):501-508. PubMed ID: 37914579
[TBL] [Abstract][Full Text] [Related]
13. Integration of surgery and systemic therapy in the management of metastatic renal cancer.
Thomas AA; Rini BI; Campbell SC
Curr Urol Rep; 2009 Jan; 10(1):35-41. PubMed ID: 19116094
[TBL] [Abstract][Full Text] [Related]
14. Isolated soft tissue mass of the finger as the first presentation of oligometastatic renal cell carcinoma.
Hopkins DT; Waters D; Manecksha RP; Lynch TH
BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35580945
[TBL] [Abstract][Full Text] [Related]
15. Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Battaglia A; De Meerleer G; Tosco L; Moris L; Van den Broeck T; Devos G; Everaerts W; Joniau S
Eur Urol Oncol; 2019 Mar; 2(2):174-188. PubMed ID: 31017094
[TBL] [Abstract][Full Text] [Related]
16. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma.
Bhindi B; Abel EJ; Albiges L; Bensalah K; Boorjian SA; Daneshmand S; Karam JA; Mason RJ; Powles T; Bex A
Eur Urol; 2019 Jan; 75(1):111-128. PubMed ID: 30467042
[TBL] [Abstract][Full Text] [Related]
17. Multimodal treatment of advanced renal cancer in 2017.
Mennitto A; Verzoni E; Grassi P; Ratta R; Fucà G; Procopio G
Expert Rev Clin Pharmacol; 2017 Dec; 10(12):1395-1402. PubMed ID: 28956645
[TBL] [Abstract][Full Text] [Related]
18. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.
Singla N; Hutchinson RC; Ghandour RA; Freifeld Y; Fang D; Sagalowsky AI; Lotan Y; Bagrodia A; Margulis V; Hammers HJ; Woldu SL
Urol Oncol; 2020 Jun; 38(6):604.e9-604.e17. PubMed ID: 32253116
[TBL] [Abstract][Full Text] [Related]
19. Current Approaches to the Treatment of Advanced or Metastatic Renal Cell Carcinoma.
Tenold M; Ravi P; Kumar M; Bowman A; Hammers H; Choueiri TK; Lara PN
Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-10. PubMed ID: 32239988
[TBL] [Abstract][Full Text] [Related]
20. Integration of surgery and systemic therapy for renal cell carcinoma.
Kenney PA; Wood CG
Urol Clin North Am; 2012 May; 39(2):211-31, vii. PubMed ID: 22487764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
